We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Assessment of cardiac dysfunction in a randomized trial comparing doxorubicin and cyclophosphamide followed by paclitaxel, with or without trastuzumab as adjuvant therapy in node-positive, human epidermal growth factor receptor 2-overexpressing breast cancer: NSABP B-31.
- Authors
Tan-Chiu, Elizabeth; Yothers, Greg; Romond, Edward; Geyer, Charles E, Jr; Ewer, Michael; Keefe, Deborah; Shannon, Richard P; Swain, Sandra M; Brown, Ann; Fehrenbacher, Louis; Vogel, Victor G; Seay, Thomas E; Rastogi, Priya; Mamounas, Eleftherios P; Wolmark, Norman; Bryant, John
- Abstract
Trastuzumab is effective in treating human epidermal growth factor receptor 2 (HER2) -positive breast cancer, but it increases frequency of cardiac dysfunction (CD) when used with or after anthracyclines.
- Publication
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2005, Vol 23, Issue 31, p7811
- ISSN
0732-183X
- Publication type
Journal Article
- DOI
10.1200/JCO.2005.02.4091